(Q42936157)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Adrian Curran

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Inma Ocana

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Mar Gutirerrez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Elisabet Deig

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Gracia Mateo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Rosa Maria Lopez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Arkaitz Imaz

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Manuel Crespo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Pere Domingo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

language of work or name

English

0 references

publication date

16 August 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

Journal of Antimicrobial Chemotherapy

10 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

2195-2203

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20713406%20AND%20SRC:MED&resulttype=core&format=json

Better adherence with once-daily antiretroviral regimens: a meta-analysis

10 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

Assessing the reliability of two toxicity scales: implications for interpreting toxicity data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295

Double-boosted protease inhibitor antiretroviral regimens: what role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKQ295